Protalix BioTherapeutics (PLX) EBITDA Margin (2010 - 2026)
Protalix BioTherapeutics' (PLX) quarterly EBITDA Margin came in at 62.65% in Q1 2026, up 10364.0% year-on-year from N/an in Q1 2025, and up 222.7% quarter-over-quarter from 51.06% in Q4 2025.
Protalix BioTherapeutics (PLX) EBITDA Margin (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' EBITDA Margin history runs 17 years deep, the most recent figure standing at 62.65% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 10364.0% year-over-year to 62.65% in Q1 2026; TTM through Mar 2026 was 25.91%, a 1817.0% increase from a year earlier, with the FY2025 full-year figure at 10.43%, down 1776.0% from the prior year.
- EBITDA Margin grew to 62.65% in Q1 2026 per PLX's latest filing, from 51.06% in the prior quarter.
- Across five years, EBITDA Margin topped out at 62.65% in Q1 2026 and bottomed at 129.56% in Q1 2024.
- The 5-year median for EBITDA Margin is 18.24% (2023), against an average of 15.33%.
- Across the five-year window, EBITDA Margin jumped 12133 bps in 2023 and sank 10392 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 28.95% in 2022, then slumped by 85 bps to 53.55% in 2023, then surged by 174 bps to 39.57% in 2024, then tumbled by 229 bps to 51.06% in 2025, then surged by 223 bps to 62.65% in 2026.
- Per Business Quant, the three latest PLX EBITDA Margin figures stand at 62.65% (Q1 2026), 51.06% (Q4 2025), and 11.94% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn | 62.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.65% |
| Dec 31, 2025 | -51.06% |
| Sep 30, 2025 | 11.94% |
| Jun 30, 2025 | 7.48% |
| Mar 31, 2025 | -40.99% |
| Dec 31, 2024 | 39.57% |
| Sep 30, 2024 | 22.22% |
| Jun 30, 2024 | -18.01% |
| Mar 31, 2024 | -129.56% |
| Dec 31, 2023 | -53.55% |
| Sep 30, 2023 | -18.24% |
| Jun 30, 2023 | 58.22% |
| Mar 31, 2023 | -25.65% |
| Dec 31, 2022 | -28.95% |
| Sep 30, 2022 | -22.03% |
| Jun 30, 2022 | -63.11% |
| Mar 31, 2022 | -11.63% |
| Dec 31, 2021 | -66.74% |
| Sep 30, 2021 | -15.64% |
| Jun 30, 2021 | -142.62% |